HER-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer

Journal of Clinical Oncology

Volumn 21, Issue 3, 2003, Pages 453-457

  Love, Richard R ^a   Duc, Nguyen Ba ^a   Havighurst, Thomas C ^a   Mohsin, Syed K ^a   Zhang, Qian ^a   DeMets, David L ^a   Allred, D Craig ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE INTERVAL; FEMALE; GENE OVEREXPRESSION; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARIECTOMY; OVERALL SURVIVAL; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; ADULT; BIOSYNTHESIS; BREAST TUMOR; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; RISK; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; ODDS RATIO; OVARIECTOMY; PREMENOPAUSE; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TAMOXIFEN; TREATMENT OUTCOME;

EID: 0037313834     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.10.133     Document Type: Article

References (23)

1. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998
2. Early Breast Cancer Trialists' Collaborative Group: Ovarian ablation in early breast cancer: Overview of the randomised trials. Lancet 348:1189-1196, 1996
3. Yamauchi H, Stearns V, Hayes DF: When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19:2334-2356, 2001
4. Carlomagno C, Perrone F, Gallo C, et al: c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14:2702-2708, 1996
5. Bianco AR, De Laurentiis M, Carlomagno C, et al: HER2 overexpression predicts adjuvant tamoxifen failure for early breast cancer: Complete data at 20 yr of the Naples GUN randomized trial. Proc Am Soc Clin Oncol 19:75a, 2000 (abstr)
6. Berry DA, Muss HB, Thor AD, et al: HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 18:3471-3479, 2000
7. Tetu B, Brisson J: Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 73:2359-2365, 1994
8. Borg A, Baldetorp B, Ferno M, et al: ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81:137-144, 1994
9. Sjogren S, Inganas M, Lindgren A, et al: Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 16:462-469, 1998
10. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001
11. Andrulis IL, Bull SB, Blackstein ME, et al: Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16:1340-1349, 1998
12. Love RR, Duc NB, Allred DC, et al: Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol 20:2559-2566, 2002
13. Allred DC, Harvey JM, Berardo M, et al: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155-168, 1998
14. Elledge RM, Green S, Ciocca D, et al: HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group Study. Clin Cancer Res 4:7-12, 1998
15. Chang J, Powles TJ, Allred DC, et al: Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 17:3058-3063, 2000
16. Agresti A: Categorical Data Analysis. New York, Wiley, 1990
17. Cox DR: Regression models and life-tables. J R Stat Soc Ser B 34:187-202, 1972
18. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
19. Mantel M: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
20. Gail M, Simon R: Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 41:361-372, 1985
21. Allred DC, Swanson PE: Testing for erbB-2 by immunohistochemistry in breast cancer. Am J Clin Pathol 113:171-175, 2000
22. Knoop AS, Bentzen SM, Nielsen MM, et al: Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 19:3376-3384, 2001
23. Benz CC, Scott GK, Sarup JC, et al: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:85-95, 1993